Venus Remedies Complete Financial Statements
VENUSREM • Review detailed financials to uncover trends, confirm thesis & journal trades
11 Years of Data
2025 - 2015
Complete Financial Data Export
Export complete financial statements for Venus Remedies (VENUSREM).
Downloads include all available records across all periods.
For market performance, see the
VENUSREM stock price today
.
Profitability Ratios
Net Profit Margin
10.26%
2025 data
EBITDA Margin
16.92%
2025 data
Operating Margin
16.00%
2025 data
Return on Assets
2.79%
2025 data
Return on Equity
3.57%
2025 data
Balance Sheet Ratios
Current Ratio
23.79
2025 data
Debt to Equity
1.28
2025 data
Equity Ratio
78.35%
2025 data
Asset Turnover
0.27
2025 data
Year-over-Year Growth Analysis
Comparing Sept 2024 vs Sept 2025
Revenue Growth
+9.6%
Year-over-Year
Net Profit Growth
+400.0%
Year-over-Year
EBITDA Growth
+106.3%
Year-over-Year
Expense Growth
-0.6%
Year-over-Year
Assets Growth
+14.2%
Year-over-Year
Equity Growth
+15.0%
Year-over-Year
Liabilities Growth
+14.2%
Year-over-Year
Operating Cash Flow Growth
+132.4%
Year-over-Year
Investing Cash Flow Growth
-755.6%
Year-over-Year
Income Statement
Periods
₹ Crores
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195 | 202 | 141 | 178 | 199 | 110 | 189 | 171 | 159 | 97 | 146 | 142 | 145 | 145 | 121 | 205 | 135 | 132 | 126 | 146 | 84 | 191 | 128 | 89 | 95 | 75 | 99 | 92 | 68 | 77 |
| Expenses | 162 | 166 | 122 | 163 | 176 | 97 | 159 | 150 | 131 | 85 | 131 | 127 | 137 | 129 | 109 | 175 | 107 | 113 | 112 | 115 | 84 | 177 | 104 | 75 | 98 | 64 | 86 | 72 | 57 | 71 |
| EBITDA | 33 | 36 | 19 | 16 | 23 | 13 | 30 | 21 | 28 | 13 | 14 | 15 | 8 | 16 | 12 | 30 | 29 | 19 | 14 | 31 | 0 | 13 | 24 | 14 | -3 | 11 | 13 | 19 | 11 | 6 |
| Operating Profit Margin % | 16.00% | 15.00% | 11.00% | 4.00% | 10.00% | 10.00% | 10.00% | 11.00% | 16.00% | 11.00% | 8.00% | 9.00% | 4.00% | 10.00% | 7.00% | 13.00% | 4.00% | 13.00% | 10.00% | 8.00% | -2.00% | 6.00% | 15.00% | 14.00% | -8.00% | 13.00% | 11.00% | 18.00% | 15.00% | 6.00% |
| Depreciation | 6 | 5 | 6 | 6 | 6 | 6 | 5 | 6 | 8 | 8 | 7 | 9 | 8 | 8 | 7 | 9 | 9 | 9 | 9 | 9 | 7 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 7 | -2 | 3 | 2 | 5 | 0 | 6 | 4 | 11 | 8 | 10 |
| Profit Before Tax | 27 | 31 | 13 | 9 | 18 | 7 | 25 | 14 | 20 | 5 | 8 | 6 | 0 | 8 | 5 | 22 | 18 | 10 | 5 | 15 | -5 | 2 | 14 | 1 | -12 | -4 | 0 | 0 | -6 | -12 |
| Tax | 6 | 10 | 3 | 6 | 7 | 6 | 5 | 4 | 9 | 4 | 1 | 0 | 0 | 1 | 1 | -2 | -17 | -2 | -1 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | -1 | 0 | -1 |
| Net Profit | 20 | 21 | 10 | 4 | 11 | 1 | 20 | 10 | 11 | 1 | 7 | 5 | 0 | 7 | 3 | 23 | 35 | 12 | 6 | 13 | -5 | 2 | 12 | 0 | -12 | -4 | -1 | 0 | -6 | -12 |
| Earnings Per Share (₹) | 15.06 | 15.71 | 7.18 | 2.63 | 7.86 | 0.92 | 14.66 | 7.44 | 8.27 | 0.88 | 5.13 | 3.99 | 0.17 | 5.16 | 2.46 | 17.32 | 28.45 | 8.86 | 4.22 | 10.55 | -4.38 | 1.60 | 9.44 | 0.34 | -9.29 | -3.30 | -0.78 | 0.34 | -4.70 | -9.50 |
Related Pages for Venus Remedies
Additional stock information and data for VENUSREM
Balance Sheet
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 716 | 627 | 601 | 580 | 556 | 644 | 733 | 751 | 765 | 843 | 841 |
| Current Assets | 452 | 360 | 323 | 278 | 234 | 294 | 265 | 260 | 259 | 277 | 233 |
| Fixed Assets | 229 | 219 | 216 | 241 | 262 | 289 | 364 | 389 | 406 | 453 | 444 |
| Capital Work in Progress | 26 | 21 | 26 | 25 | 25 | 25 | 65 | 65 | 66 | 80 | 78 |
| Investments | 84 | 19 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 376 | 368 | 339 | 314 | 269 | 330 | 304 | 297 | 293 | 310 | 319 |
| LIABILITIES | |||||||||||
| Total Liabilities | 716 | 627 | 601 | 580 | 556 | 644 | 733 | 751 | 765 | 843 | 841 |
| Current Liabilities | 19 | 60 | 58 | 47 | 58 | 96 | 137 | 159 | 180 | 212 | 222 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 561 | 488 | 460 | 440 | 400 | 323 | 333 | 362 | 389 | 438 | 457 |
| Share Capital | 13 | 13 | 13 | 13 | 12 | 12 | 12 | 12 | 12 | 11 | 11 |
| Reserves & Surplus | 548 | 474 | 447 | 427 | 374 | 311 | 320 | 350 | 376 | 426 | 445 |
Cash Flow Statement
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 86 | 37 | 37 | 41 | 132 | 78 | 45 | 31 | 59 | 47 | 68 |
| Investing Activities | -77 | -9 | -58 | -17 | 57 | -5 | -11 | 9 | -18 | 3 | -67 |
| Financing Activities | -1 | -1 | -1 | -10 | -162 | -73 | -35 | -39 | -44 | -46 | -1 |
| Net Cash Flow | 9 | 28 | -22 | 14 | 27 | 0 | -1 | 0 | -4 | 4 | -1 |